These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

434 related items for PubMed ID: 33356392

  • 21. Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.
    Schwartz GG, Steg PG, Szarek M, Bittner VA, Diaz R, Goodman SG, Kim YU, Jukema JW, Pordy R, Roe MT, White HD, Bhatt DL, ODYSSEY OUTCOMES Committees and Investigators*.
    Circulation; 2020 May 19; 141(20):1608-1617. PubMed ID: 32223446
    [Abstract] [Full Text] [Related]

  • 22. Effects of 20 mg rosuvastatin on VLDL1-, VLDL2-, IDL- and LDL-ApoB kinetics in type 2 diabetes.
    Vergès B, Florentin E, Baillot-Rudoni S, Monier S, Petit JM, Rageot D, Gambert P, Duvillard L.
    Diabetologia; 2008 Aug 19; 51(8):1382-90. PubMed ID: 18535816
    [Abstract] [Full Text] [Related]

  • 23. The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism.
    Marston NA, Gurmu Y, Melloni GEM, Bonaca M, Gencer B, Sever PS, Pedersen TR, Keech AC, Roselli C, Lubitz SA, Ellinor PT, O'Donoghue ML, Giugliano RP, Ruff CT, Sabatine MS.
    Circulation; 2020 May 19; 141(20):1600-1607. PubMed ID: 32223429
    [Abstract] [Full Text] [Related]

  • 24. Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol.
    Colhoun HM, Leiter LA, Müller-Wieland D, Cariou B, Ray KK, Tinahones FJ, Domenger C, Letierce A, Israel M, Samuel R, Del Prato S.
    Cardiovasc Diabetol; 2020 Feb 08; 19(1):14. PubMed ID: 32035487
    [Abstract] [Full Text] [Related]

  • 25. In vivo studies of VLDL metabolism and LDL heterogeneity.
    Demant T, Packard C.
    Eur Heart J; 1998 Jul 08; 19 Suppl H():H7-10. PubMed ID: 9717058
    [Abstract] [Full Text] [Related]

  • 26. Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans.
    Reyes-Soffer G, Pavlyha M, Ngai C, Thomas T, Holleran S, Ramakrishnan R, Karmally W, Nandakumar R, Fontanez N, Obunike J, Marcovina SM, Lichtenstein AH, Matthan NR, Matta J, Maroccia M, Becue F, Poitiers F, Swanson B, Cowan L, Sasiela WJ, Surks HK, Ginsberg HN.
    Circulation; 2017 Jan 24; 135(4):352-362. PubMed ID: 27986651
    [Abstract] [Full Text] [Related]

  • 27. Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy.
    Pradhan AD, Aday AW, Rose LM, Ridker PM.
    Circulation; 2018 Jul 10; 138(2):141-149. PubMed ID: 29716940
    [Abstract] [Full Text] [Related]

  • 28. Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER.
    Sabatine MS, De Ferrari GM, Giugliano RP, Huber K, Lewis BS, Ferreira J, Kuder JF, Murphy SA, Wiviott SD, Kurtz CE, Honarpour N, Keech AC, Sever PS, Pedersen TR.
    Circulation; 2018 Aug 21; 138(8):756-766. PubMed ID: 29626068
    [Abstract] [Full Text] [Related]

  • 29. n-3 Polyunsaturated Fatty Acid Supplementation Has No Effect on Postprandial Triglyceride-Rich Lipoprotein Kinetics in Men with Type 2 Diabetes.
    Tremblay AJ, Lamarche B, Hogue JC, Couture P.
    J Diabetes Res; 2016 Aug 21; 2016():2909210. PubMed ID: 27034958
    [Abstract] [Full Text] [Related]

  • 30. Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies.
    Raal FJ, Hegele RA, Ruzza A, López JAG, Bhatia AK, Wu J, Wang H, Gaudet D, Wiegman A, Wang J, Santos RD.
    Arterioscler Thromb Vasc Biol; 2024 May 21; 44(5):1156-1164. PubMed ID: 38545781
    [Abstract] [Full Text] [Related]

  • 31. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.
    Kolovou V, Katsiki N, Makrygiannis S, Mavrogieni S, Karampetsou N, Manolis A, Melidonis A, Mikhailidis DP, Kolovou GD.
    J Cardiovasc Pharmacol Ther; 2021 Jan 21; 26(1):51-58. PubMed ID: 32729335
    [Abstract] [Full Text] [Related]

  • 32. Overproduction of small very low density lipoproteins (Sf 20-60) in moderate hypercholesterolemia: relationships between apolipoprotein B kinetics and plasma lipoproteins.
    Gaw A, Packard CJ, Lindsay GM, Griffin BA, Caslake MJ, Lorimer AR, Shepherd J.
    J Lipid Res; 1995 Jan 21; 36(1):158-71. PubMed ID: 7706941
    [Abstract] [Full Text] [Related]

  • 33. Enrichment of Triglyceride-Rich Lipoproteins with Apolipoprotein C-I Is Positively Associated with Their Delayed Plasma Clearance Independently of Other Transferable Apolipoproteins in Postmenopausal Overweight and Obese Women.
    Wassef H, Bissonnette S, Dufour R, Davignon J, Faraj M.
    J Nutr; 2017 May 21; 147(5):754-762. PubMed ID: 28356429
    [Abstract] [Full Text] [Related]

  • 34. Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism.
    Watts GF, Chan DC, Dent R, Somaratne R, Wasserman SM, Scott R, Burrows S, R Barrett PH.
    Circulation; 2017 Jan 24; 135(4):338-351. PubMed ID: 27941065
    [Abstract] [Full Text] [Related]

  • 35. Effects of fenofibrate on apolipoprotein kinetics in patients with coexisting dysbetalipoproteinemia and heterozygous familial hypercholesterolemia.
    Tremblay AJ, Lamarche B, Ruel IL, Hogue JC, Deshaies Y, Gagné C, Couture P.
    Atherosclerosis; 2006 Sep 24; 188(1):203-12. PubMed ID: 16337207
    [Abstract] [Full Text] [Related]

  • 36. Effects of liraglutide on the metabolism of triglyceride-rich lipoproteins in type 2 diabetes.
    Taskinen MR, Björnson E, Matikainen N, Söderlund S, Pietiläinen KH, Ainola M, Hakkarainen A, Lundbom N, Fuchs J, Thorsell A, Andersson L, Adiels M, Packard CJ, Borén J.
    Diabetes Obes Metab; 2021 May 24; 23(5):1191-1201. PubMed ID: 33502078
    [Abstract] [Full Text] [Related]

  • 37. Effect of atorvastatin on apolipoprotein B100 containing lipoprotein metabolism in type-2 diabetes.
    Ouguerram K, Magot T, Zaïr Y, Marchini JS, Charbonnel B, Laouenan H, Krempf M.
    J Pharmacol Exp Ther; 2003 Jul 24; 306(1):332-7. PubMed ID: 12684543
    [Abstract] [Full Text] [Related]

  • 38. A study of the metabolism of apolipoprotein B100 in relation to insulin resistance in African American males.
    Sumner AE, Falkner B, Diffenderfer MR, Barrett PH, Marsh JB.
    Proc Soc Exp Biol Med; 1999 Sep 24; 221(4):352-60. PubMed ID: 10460697
    [Abstract] [Full Text] [Related]

  • 39. Postprandial accumulation of chylomicrons and chylomicron remnants is determined by the clearance capacity.
    Adiels M, Matikainen N, Westerbacka J, Söderlund S, Larsson T, Olofsson SO, Borén J, Taskinen MR.
    Atherosclerosis; 2012 May 24; 222(1):222-8. PubMed ID: 22365426
    [Abstract] [Full Text] [Related]

  • 40. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.
    Hogue JC, Lamarche B, Deshaies Y, Tremblay AJ, Bergeron J, Gagné C, Couture P.
    Metabolism; 2008 Feb 24; 57(2):246-54. PubMed ID: 18191056
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.